SCHEMBL10132039

SCHEMBL10132039

O=C(CCC(=O)NC1CC1)NCCNC1CC1

nearest known ligand 0.52

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.52
SMN1; SMN2 Q16637 1/20 0.47
HPGD P15428 2/20 0.42
HDAC3 O15379 2/20 0.41
HDAC1 Q13547 2/20 0.41
HDAC2 Q92769 2/20 0.41
HDAC10 Q969S8 2/20 0.41
HDAC11 Q96DB2 2/20 0.41
HDAC8 Q9BY41 2/20 0.41
HDAC6 Q9UBN7 2/20 0.41
NCOR2 Q9Y618 1/20 0.41
SIGMAR1 Q99720 2/20 0.39
SMYD3 Q9H7B4 5/20 0.38
NPC1 O15118 1/20 0.38
RAB9A P51151 1/20 0.38
EPHX2 P34913 1/20 0.38
MEN1 O00255 1/20 0.37
MAPT P10636 1/20 0.37
KMT2A Q03164 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10132099 0.82 SMN1; SMN2 (0.53) ALDH1A1SMN1; SMN2HDAC3HDAC1HDAC2
SCHEMBL10132085 0.81 SMN1; SMN2 (0.65) ALDH1A1SMN1; SMN2HPGDHDAC3HDAC1
SCHEMBL10015691 0.77 ALDH1A1 (0.80) ALDH1A1SMN1; SMN2HPGDHDAC3HDAC1
SCHEMBL10132028 0.73 ALDH1A1 (0.40) ALDH1A1SMN1; SMN2HPGDHDAC3HDAC1
SCHEMBL15987516 0.73 ALDH1A1 (0.42) ALDH1A1SMN1; SMN2
SCHEMBL13544828 0.71 SMN1; SMN2 (0.54) ALDH1A1SMN1; SMN2HPGDHDAC3HDAC1
SCHEMBL9766476 0.71 KDM4E (0.46) ALDH1A1SMN1; SMN2
SCHEMBL10132037 0.71 RAB9A (0.40) ALDH1A1SMN1; SMN2HPGDSMYD3NPC1
SCHEMBL22797043 0.70 ALDH1A1 (0.57) ALDH1A1SMN1; SMN2HDAC3HDAC1HDAC2
SCHEMBL13453346 0.70 MEN1 (0.45) ALDH1A1SMN1; SMN2SIGMAR1EPHX2MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9012603-B2 Peptides that block the binding of IgG to FcRn BIOGEN IDEC HEMOPHILIA INC. (US) 2015-04-21 US disclosed
US-8906844-B2 Immunomodulatory peptides BIOGEN IDEC HEMOPHILIA INC. (US) 2014-12-09 US disclosed
US-8101186-B2 Peptides that block the binding of IgG to FcRn SYNTONIX PHARMACEUTICALS, INC. (US) 2012-01-24 US disclosed
US-20110230639-A1 IMMUNOMODULATORY PEPTIDES SYNTONIX PHARMACEUTICALS INC. (US) 2011-09-22 US disclosed
US-20110059889-A1 PEPTIDES THAT BLOCK THE BINDING OF IgG TO FcRn SYNTONIX PHARMACEUTICALS, INC. 2011-03-10 US disclosed
US-20070254831-A1 PEPTIDES THAT BLOCK THE BINDING OF IgG to FcRn BIOGEN HEMOPHILIA INC. 2007-11-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110059889-A1 PEPTIDES THAT BLOCK THE BINDING OF IgG TO FcRn FCGRT, FCGR3B, FCGR1A ALDH1A1 4835/4885SMN1; SMN2 4722/4885HPGD 3932/4885
US-20070254831-A1 PEPTIDES THAT BLOCK THE BINDING OF IgG to FcRn FCGRT, FCGR3B, FCGR1A ALDH1A1 4835/4885SMN1; SMN2 4722/4885HPGD 3932/4885
US-20110230639-A1 IMMUNOMODULATORY PEPTIDES FCGRT, FCGR3B, FCGR2A ALDH1A1 4501/4885SMN1; SMN2 3745/4885HPGD 2889/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.